Novel anti-melanoma immunotherapies: Disarming tumor escape mechanisms

Clinical and Developmental Immunology

Volumn 2012, Issue , 2012, Pages

  Sapoznik, Sivan ^a   Hammer, Ohad ^b   Ortenberg, Rona ^a,c   Besser, Michal J ^a,c   Ben Moshe, Tehila ^d   Schachter, Jacob ^a   Markel, Gal ^a,c  

^a SHEBA MEDICAL CENTER   (Israel)

^b Pontifax Venture   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

^d cCAM Biotherapeutics Ltd   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE 1; CP 870 893; CT 011; CT 1101; DACARBAZINE; IPILIMUMAB; MDX 1105 01; MK 3475; MP 224; NIVOLUMAB; TICILIMUMAB; TRX 518; UNCLASSIFIED DRUG; URELUMAB; MONOCLONAL ANTIBODY;

ADOPTIVE T CELL TRANSFER; APOPTOSIS; ARTICLE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CELL INTERACTION; CELL PROLIFERATION; CELL TRANSFER; COLORECTAL CANCER; CYTOKINE RELEASE; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HUMAN; KIDNEY CARCINOMA; LEUKEMIA; LIGAND BINDING; LUNG NON SMALL CELL CANCER; LYMPHOMA; MELANOMA; MULTIPLE MYELOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER; SKIN DISEASE; SURVIVAL RATE; SURVIVAL TIME; T LYMPHOCYTE ACTIVATION; TUMOR ESCAPE; UNSPECIFIED SIDE EFFECT; ADOPTIVE TRANSFER; ECONOMICS; IMMUNOLOGY; IMMUNOTHERAPY; METHODOLOGY; REVIEW; T LYMPHOCYTE;

ADOPTIVE TRANSFER; ANTIBODIES, MONOCLONAL; HUMANS; IMMUNOTHERAPY; MELANOMA; T-LYMPHOCYTES; TUMOR ESCAPE;

EID: 84863689866     PISSN: 17402522     EISSN: 17402530     Source Type: Journal    
DOI: 10.1155/2012/818214     Document Type: Article

References (89)

1. Vesely M. D., Kershaw M. H., Schreiber R. D., Smyth M. J., Natural innate and adaptive immunity to cancer Annual Review of Immunology 2011 29 235 271
2. Quezada S. A., Peggs K. S., Simpson T. R., Allison J. P., Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication Immunological Reviews 2011 241 1 104 118
3. Schreiber R. D., Old L. J., Smyth M. J., Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion Science 2011 331 6024 1565 1570
4. Stewart T. J., Abrams S. I., How tumours escape mass destruction Oncogene 2008 27 45 5894 5903
5. Poschke I., Mougiakakos D., Kiessling R., Camouflage and sabotage: tumor escape from the immune system Cancer Immunology, Immunotherapy 2011 60 8 1161 1171
6. Yaguchi T., Sumimoto H., Kudo-Saito C., Tsukamoto N., Ueda R., Iwata-Kajihara T., Nishio H., Kawamura N., Kawakami Y., The mechanisms of cancer immunoescape and development of overcoming strategies International Journal of Hematology 2011 93 3 294 300
7. Balch C. M., Houghton A. N., Sober A. J., Soong S.-J., Cutaneous Melanoma 2003 4th Quality Medical Publishing
8. Slominski A., Wortsman J., Carlson A. J., Matsuoka L. Y., Balch C. M., Mihm M. C., Malignant melanoma Archives of Pathology and Laboratory Medicine 2001 125 10 1295 1306
9. Jemal A., Siegel R., Ward E., Murray T., Xu J., Thun M. J., Cancer statistics, 2007 Ca-A Cancer Journal for Clinicians 2007 57 1 43 66 (Pubitemid 46148091)
10. Klein O., Schmidt C., Knights A., Davis I. D., Chen W., Cebon J., Melanoma vaccines: developments over the past 10 years Expert Review of Vaccines 2011 10 6 853 873
11. Rosenberg S. A., Restifo N. P., Yang J. C., Morgan R. A., Dudley M. E., Adoptive cell transfer: a clinical path to effective cancer immunotherapy Nature Reviews Cancer 2008 8 4 299 308 (Pubitemid 351430867)
12. Shepherd C., Puzanov I., Sosman J. A., B-RAF inhibitors: an evolving role in the therapy of malignant melanoma Current Oncology Reports 2010 12 3 146 152
13. Weber J., Immune checkpoint proteins: a new therapeutic paradigm for cancerpreclinical background: CTLA-4 and PD-1 blockade Seminars in Oncology 2010 37 5 430 439
14. Yuan J., Page D. B., Ku G. Y., Li Y., Mu Z., Ariyan C., Gallardo H. F., Roman R. A., Heine A. I., Terzulli S. L., Gnjatic S., Ritter G., Jungbluth A. A., Allison J. P., Old L. J., Wolchok J. D., Correlation of clinical and immunological data in a metastatic melanoma patient with heterogeneous tumor responses to ipilimumab therapy Cancer Immunity 2010 10, article 1
15. Rosenberg S. A., Sherry R. M., Morton K. E., Scharfman W. J., Yang J. C., Topalian S. L., Royal R. E., Kammula U., Restifo N. P., Hughes M. S., Schwartzentruber D., Berman D. M., Schwarz S. L., Ngo L. T., Mavroukakis S. A., White D. E., Steinberg S. M., Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8 + T cells in patients with melanoma Journal of Immunology 2005 175 9 6169 6176 (Pubitemid 41508105)
16. Anichini A., Vegetti C., Mortarini R., The paradox of T cell-mediated antitumor immunity in spite of poor clinical outcome in human melanoma Cancer Immunology, Immunotherapy 2004 53 10 855 864 (Pubitemid 39312653)
17. Harlin H., Kuna T. V., Peterson A. C., Meng Y., Gajewski T. F., Tumor progression despite massive influx of activated CD8 + T cells in a patient with malignant melanoma ascites Cancer Immunology, Immunotherapy 2006 55 10 1185 1197 (Pubitemid 43992045)
18. Alegre M. L., Shiels H., Thompson C. B., Gajewski T. F., Expression and function of CTLA-4 in Th1 and Th2 cells Journal of Immunology 1998 161 7 3347 3356
19. Munn D. H., Sharma M. D., Mellor A. L., Ligation of B7-1/B7-2 by human CD4 + T cells triggers indoleamine 2,3-dioxygenase activity in dendritic cells Journal of Immunology 2004 172 7 4100 4110 (Pubitemid 38375222)
20. Contardi E., Palmisano G. L., Tazzari P. L., Martelli A. M., Fal F., Fabbi M., Kato T., Lucarelli E., Donati D., Polito L., Bolognesi A., Ricci F., Salvi S., Gargaglione V., Mantero S., Alberghini M., Ferrara G. B., Pistillo M. P., CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction International Journal of Cancer 2005 117 4 538 550 (Pubitemid 41504541)
21. Shah K. V., Chien A. J., Yee C., Moon R. T., CTLA-4 is a direct target of Wnt/ -catenin signaling and is expressed in human melanoma tumors Journal of Investigative Dermatology 2008 128 12 2870 2879
22. Queirolo P., Boitano M., Carrega P., Targeting CTLA-4 directly on melanoma cells: a possible novel perspective in the immunotherapy of cutaneous melanoma Journal of Clinical Oncology 2009 27 supplement, abstract e22138
23. Weber J. S., Tumor evasion may occur via expression of regulatory molecules: a case for CTLA-4 in melanoma Journal of Investigative Dermatology 2008 128 12 2750 2752
24. Tivol E. A., Borriello F., Schweitzer A. N., Lynch W. P., Bluestone J. A., Sharpe A. H., Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4 Immunity 1995 3 5 541 547
25. Waterhouse P., Penninger J. M., Timms E., Wakeham A., Shahinian A., Lee K. P., Thompson C. B., Griesser H., Mak T. W., Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4 Science 1995 270 5238 985 988
26. van Ginderachter J. A., Liu Y., Geldhof A. B., Brijs L., Thielemans K., B7-1, IFN gamma and anti-CTLA-4 co-operate to prevent T-cell tolerization during immunotherapy against a murine T-lymphoma International Journal of Cancer 2000 87 539 547 (Pubitemid 30639814)
27. Hurwitz A. A., Foster B. A., Kwon E. D., Truong T., Choi E. M., Greenberg N. M., Burg M. B., Allison J. P., Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade Cancer Research 2000 60 9 2444 2448 (Pubitemid 30262435)
28. Kwon E. D., Hurwitz A. A., Foster B. A., Madias C., Feldhaus A. L., Greenberg N. M., Burg M. B., Allison J. P., Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer Proceedings of the National Academy of Sciences of the United States of America 1997 94 15 8099 8103 (Pubitemid 27343783)
29. Leach D. R., Krummel M. F., Allison J. P., Enhancement of antitumor immunity by CTLA-4 blockade Science 1996 271 5256 1734 1736 (Pubitemid 26102823)
30. Hodi F. S., O'Day S. J., McDermott D. F., Weber R. W., Sosman J. A., Haanen J. B., Gonzalez R., Robert C., Schadendorf D., Hassel J. C., Akerley W., Van Den Eertwegh A. J. M., Lutzky J., Lorigan P., Vaubel J. M., Linette G. P., Hogg D., Ottensmeier C. H., Lebbé C., Peschel C., Quirt I., Clark J. I., Wolchok J. D., Weber J. S., Tian J., Yellin M. J., Nichol G. M., Hoos A., Urba W. J., Improved survival with ipilimumab in patients with metastatic melanoma The New England Journal of Medicine 2010 363 8 711 723
31. Robert C., Thomas L., Bondarenko I., O'Day S., Weber J., Garbe C., Lebbe C., Baurain J. F., Testori A., Grob J. J., Davidson N., Richards J., Maio M., Hauschild A., Miller W. H., Gascon P., Lotem M., Harmankaya K., Ibrahim R., Francis S., Chen T. T., Humphrey R., Hoos A., Wolchok J. D., Ipilimumab plus dacarbazine for previously untreated metastatic melanoma The New England Journal of Medicine 2011 364 26 2517 2526
32. Ipilimumab Drugs in R D 2010 10 2 97 110
33. Fife B. T., Pauken K. E., The role of the PD-1 pathway in autoimmunity and peripheral tolerance Annals of the New York Academy of Sciences 2011 1217 1 45 59
34. Ishida M., Iwai Y., Tanaka Y., Okazaki T., Freeman G. J., Minato N., Honjo T., Differential expression of PD-L1 and PD-L2, ligands for an inhibitory receptor PD-1, in the cells of lymphohematopoietic tissues Immunology Letters 2002 84 1 57 62 (Pubitemid 34879920)
35. Loke P., Allison J. P., PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells Proceedings of the National Academy of Sciences of the United States of America 2003 100 9 5336 5341 (Pubitemid 36542706)
36. Latchman Y., Wood C. R., Chernova T., Chaudhary D., Borde M., Chernova I., Iwai Y., Long A. J., Brown J. A., Nunes R., Greenfield E. A., Bourque K., Boussiotis V. A., Carter L. L., Carreno B. M., Malenkovich N., Nishimura H., Okazaki T., Honjo T., Sharpe A. H., Freeman G. J., PD-L2 is a second ligand for PD-1 and inhibits T cell activation Nature Immunology 2001 2 3 261 268 (Pubitemid 33706004)
37. Zhang Y., Chung Y., Bishop C., Daugherty B., Chute H., Holst P., Kurahara C., Lott F., Sun N., Welcher A. A., Dong C., Regulation of T cell activation and tolerance by PDL2 Proceedings of the National Academy of Sciences of the United States of America 2006 103 31 11695 11700 (Pubitemid 44182513)
38. Dong H., Strome S. E., Salomao D. R., Tamura H., Hirano F., Flies D. B., Roche P. C., Lu J., Zhu G., Tamada K., Lennon V. A., Cells E., Chen L., Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion Nature Medicine 2002 8 8 793 800
39. Iwai Y., Ishida M., Tanaka Y., Okazaki T., Honjo T., Minato N., Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade Proceedings of the National Academy of Sciences of the United States of America 2002 99 19 12293 12297
40. Riley J. L., PD-1 signaling in primary T cells Immunological Reviews 2009 229 1 114 125
41. Nishimura H., Nose M., Hiai H., Minato N., Honjo T., Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor Immunity 1999 11 2 141 151 (Pubitemid 29428807)
42. Nishimura H., Okazaki T., Tanaka Y., Nakatani K., Hara M., Matsumori A., Sasayama S., Mizoguchi A., Hiai H., Minato N., Honjo T., Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice Science 2001 291 5502 319 322 (Pubitemid 32096320)
43. Blank C., Brown I., Peterson A. C., Spiotto M., Iwai Y., Honjo T., Gajewski T. F., PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T Cell receptor (TCR) transgenic CD8 + T cells Cancer Research 2004 64 3 1140 1145 (Pubitemid 38176921)
44. Zhang L., Gajewski T. F., Kline J., PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model Blood 2009 114 8 1545 1552
45. Iwai Y., Terawaki S., Honjo T., PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells International Immunology 2005 17 2 133 144 (Pubitemid 40246578)
46. Iwai Y., Terawaki S., Ikegawa M., Okazaki T., Honjo T., PD-1 inhibits antiviral immunity at the effector phase in the liver Journal of Experimental Medicine 2003 198 1 39 50 (Pubitemid 36870184)
47. Hirano F., Kaneko K., Tamura H., Dong H., Wang S., Ichikawa M., Rietz C., Flies D. B., Lau J. S., Zhu G., Tamada K., Chen L., Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity Cancer Research 2005 65 3 1089 1096 (Pubitemid 40216472)
48. Strome S. E., Dong H., Tamura H., Voss S. G., Flies D. B., Tamada K., Salomao D., Cheville J., Hirano F., Lin W., Kasperbauer J. L., Ballman K. V., Chen L., B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma Cancer Research 2003 63 19 6501 6505 (Pubitemid 37255203)
49. Durgan K., Ali M., Warner P., Latchman Y. E., Targeting NKT cells and PD-L1 pathway results in augmented anti-tumor responses in a melanoma model Cancer Immunology, Immunotherapy 2011 60 4 547 558
50. Kronig H., Falchner K. J., Odendahl M., Brackertz B., Conrad H., PD-1 expression on melanA-reactive T-cells increases during progression to metastatic disease International Journal of Cancer 2011 130 10 2327 2336
51. Fourcade J., Sun Z., Benallaoua M., Guillaume P., Luescher I. F., Sander C., Kirkwood J. M., Kuchroo V., Zarour H. M., Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8 + T cell dysfunction in melanoma patients Journal of Experimental Medicine 2010 207 10 2175 2186
52. Brahmer J. R., Drake C. G., Wollner I., Powderly J. D., Picus J., Sharfman W. H., Stankevich E., Pons A., Salay T. M., McMiller T. L., Gilson M. M., Wang C., Selby M., Taube J. M., Anders R., Chen L., Korman A. J., Pardoll D. M., Lowy I., Topalian S. L., Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates Journal of Clinical Oncology 2010 28 19 3167 3175
53. Berger R., Rotem-Yehudar R., Slama G., Landes S., Kneller A., Leiba M., Koren-Michowitz M., Shimoni A., Nagler A., Phase i safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies Clinical Cancer Research 2008 14 10 3044 3051
54. Sznol M., Powderly J., Smith D., Safety and antitumor activity of biweekly MDX-1106 (Anti-PD-1, BMS-936558/ONO-4538) in patients with advanced refractory malignancies Journal of Clinical Oncology 2010 28 supplement 15s, abstract 2506
55. Curran M. A., Montalvo W., Yagita H., Allison J. P., PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors Proceedings of the National Academy of Sciences of the United States of America 2010 107 9 4275 4280
56. Gray-Owen S. D., Blumberg R. S., CEACAM1: contact-dependent control of immunity Nature Reviews Immunology 2006 6 6 433 446
57. Kuespert K., Pils S., Hauck C. R., CEACAMs: their role in physiology and pathophysiology Current Opinion in Cell Biology 2006 18 5 565 571 (Pubitemid 44332912)
58. Ebrahimnejad A., Streichert T., Nollau P., Horst A. K., Wagener C., Bamberger A. M., Brmmer J., CEACAM1 enhances invasion and migration of melanocytic and melanoma cells American Journal of Pathology 2004 165 5 1781 1787 (Pubitemid 39435175)
59. Gambichler T., Grothe S., Rotterdam S., Altmeyer P., Kreuter A., Protein expression of carcinoembryonic antigen cell adhesion molecules in benign and malignant melanocytic skin lesions American Journal of Clinical Pathology 2009 131 6 782 787
60. Thies A., Moll I., Berger J., Wagener C., Brmmer J., Schulze H. J., Brunner G., Schumacher U., CEACAM1 expression in cutaneous malignant melanoma predicts the development of metastatic disease Journal of Clinical Oncology 2002 20 10 2530 2536 (Pubitemid 34525740)
61. Brmmer J., Ebrahimnejad A., Flayeh R., Schumacher U., Lning T., Bamberger A. M., Wagener C., cis interaction of the cell adhesion molecule CEACAM1 with itegrin 3 American Journal of Pathology 2001 159 2 537 546 (Pubitemid 32751084)
62. Markel G., Wolf D., Hanna J., Gazit R., Goldman-Wohl D., Lavy Y., Yagel S., Mandelboim O., Pivotal role of CEACAM1 protein in the inhibition of activated decidual lymphocyte functions Journal of Clinical Investigation 2002 110 7 943 953
63. Markel G., Seidman R., Cohen Y., Besser M. J., Sinai T. C., Treves A. J., Orenstein A., Berger R., Schachter J., Dynamic expression of protective CEACAM1 on melanoma cells during specific immune attack Immunology 2009 126 2 186 200
64. Markel G., Seidman R., Stern N., Cohen-Sinai T., Izhaki O., Katz G., Besser M., Treves A. J., Blumberg R. S., Loewenthal R., Mandelboim O., Orenstein A., Schachter J., Inhibition of human tumor-infiltrating lymphocyte effector functions by the homophilic carcinoembryonic cell adhesion molecule 1 interactions Journal of Immunology 2006 177 9 6062 6071 (Pubitemid 44628821)
65. Markel G., Mussaffi H., Ling K. L., Salio M., Gadola S., Steuer G., Blau H., Achdout H., De Miguel M., Gonen-Gross T., Hanna J., Arnon T. I., Qimron U., Volovitz I., Eisenbach L., Blumberg R. S., Porgador A., Cerundolo V., Mandelboim O., The mechanisms controlling NK cell autoreactivity in TAP2-deficient patients Blood 2004 103 5 1770 1778 (Pubitemid 38268971)
66. Markel G., Gruda R., Achdout H., Katz G., Nechama M., Blumberg R. S., Kammerer R., Zimmermann W., Mandelboim O., The critical role of residues 43R and 44Q of carcinoembryonic antigen cell adhesion molecules-1 in the protection from killing by human NK cells Journal of Immunology 2004 173 6 3732 3739 (Pubitemid 39280734)
67. Azuz-Lieberman N., Markel G., Mizrahi S., Gazit R., Hanna J., Achdout H., Gruda R., Katz G., Arnon T. I., Battat S., Zamir E., Adawi M., Mader R., Mandelboim O., The involvement of NK cells in ankylosing spondylitis International Immunology 2005 17 7 837 845 (Pubitemid 41417951)
68. Markel G., Ortenberg R., Seidman R., Sapoznik S., Koren-Morag N., Besser M. J., Bar J., Shapira R., Kubi A., Nardini G., Tessone A., Treves A. J., Winkler E., Orenstein A., Schachter J., Systemic dysregulation of CEACAM1 in melanoma patients Cancer Immunology, Immunotherapy 2010 59 2 215 230
69. Markel G., Lieberman N., Katz G., Arnon T. I., Lotem M., Drize O., Blumberg R. S., Bar-Haim E., Mader R., Eisenbach L., Mandelboim O., CD66a interactions between human melanoma and NK cells: a novel class I MHC-independent inhibitory mechanism of cytotoxicity Journal of Immunology 2002 168 6 2803 2810 (Pubitemid 34211659)
70. Markel G., Achdout H., Katz G., Ling K. L., Salio M., Gruda R., Gazit R., Mizrahi S., Hanna J., Gonen-Gross T., Arnon T. I., Lieberman N., Stren N., Nachmias B., Blumberg R. S., Steuer G., Blau H., Cerundolo V., Mussaffi H., Mandelboim O., Biological function of the soluble CEACAM1 protein and implications in TAP2-deficient patients European Journal of Immunology 2004 34 8 2138 2148 (Pubitemid 39256095)
71. Chen Z., Chen L., Qiao S. W., Nagaishi T., Blumberg R. S., Carcinoembryonic antigen-related cell adhesion molecule 1 inhibits proximal TCR signaling by targeting ZAP-70 Journal of Immunology 2008 180 9 6085 6093
72. Nagaishi T., Pao L., Lin S. H., Iijima H., Kaser A., Qiao S. W., Chen Z., Glickman J., Najjar S. M., Nakajima A., Neel B. G., Blumberg R. S., SHP1 phosphatase-dependent T cell inhibition by CEACAM1 adhesion molecule isoforms Immunity 2006 25 5 769 781 (Pubitemid 46107284)
73. Stern N., Markel G., Arnon T. I., Gruda R., Wong H., Gray-Owen S. D., Mandelboim O., Carcinoembryonic antigen (CEA) inhibits NK killing via interaction with CEA-related cell adhesion molecule 1 Journal of Immunology 2005 174 11 6692 6701 (Pubitemid 40705631)
74. Moller M. J., Kammerer R., Grunert F., von Kleist S., Biliary glycoprotein (BGP) expression on T-cells and on a natural-killer-cell sub-population International Journal of Cancer 1996 65 6 740 745 (Pubitemid 26127751)
75. Ortenberg R., Sapir Y., Raz L., Hershkovitz L., Arav A. B., Novel immunutherapy for malignant melanoma with a monoclonal antibody that blocks CEACAM1 homophilic interactions. Molecular Cancer Therapeutics. In press
76. Dudley M. E., Wunderlich J. R., Yang J. C., Sherry R. M., Topalian S. L., Restifo N. P., Royal R. E., Kammula U., White D. E., Mavroukakis S. A., Rogers L. J., Gracia G. J., Jones S. A., Mangiameli D. P., Pelletier M. M., Gea-Banacloche J., Robinson M. R., Berman D. M., Filie A. C., Abati A., Rosenberg S. A., Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma Journal of Clinical Oncology 2005 23 10 2346 2357 (Pubitemid 46218728)
77. Dudley M. E., Yang J. C., Sherry R., Hughes M. S., Royal R., Kammula U., Robbins P. F., Huang J., Citrin D. E., Leitman S. F., Wunderlich J., Restifo N. P., Thomasian A., Downey S. G., Smith F. O., Klapper J., Morton K., Laurencot C., White D. E., Rosenberg S. A., Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens Journal of Clinical Oncology 2008 26 32 5233 5239
78. Besser M. J., Shapira-Frommer R., Treves A. J., Zippel D., Itzhaki O., Hershkovitz L., Levy D., Kubi A., Hovav E., Chermoshniuk N., Shalmon B., Hardan I., Catane R., Markel G., Apter S., Ben-Nun A., Kuchuk I., Shimoni A., Nagler A., Schachter J., Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients Clinical Cancer Research 2010 16 9 2646 2655
79. Schwartzentruber D. J., Hom S. S., Dadmarz R., White D. E., Yannelli J. R., Steinberg S. M., Rosenberg S. A., Topalian S. L., In vitro predictors of therapeutic response in melanoma patients receiving tumor-infiltrating lymphocytes and interleukin-2 Journal of Clinical Oncology 1994 12 7 1475 1483 (Pubitemid 24206248)
80. Morgan R. A., Dudley M. E., Wunderlich J. R., Hughes M. S., Yang J. C., Sherry R. M., Royal R. E., Topalan S. L., Kammula U. S., Restifo N. P., Zheng Z., Nahvi A., De Vries C. R., Rogers-Freezer L. J., Mavroukakis S. A., Rosenberg S. A., Cancer regression in patients after transfer of genetically engineered lymphocytes Science 2006 314 5796 126 129 (Pubitemid 44547756)
81. Johnson L. A., Morgan R. A., Dudley M. E., Cassard L., Yang J. C., Hughes M. S., Kammula U. S., Royal R. E., Sherry R. M., Wunderlich J. R., Lee C. C. R., Restifo N. P., Schwarz S. L., Cogdill A. P., Bishop R. J., Kim H., Brewer C. C., Rudy S. F., VanWaes C., Davis J. L., Mathur A., Ripley R. T., Nathan D. A., Laurencot C. M., Rosenberg S. A., Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen Blood 2009 114 3 535 546
82. Ramos C. A., Dotti G., Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy Expert Opinion on Biological Therapy 2011 11 7 855 873
83. Yvon E., del Vecchio M., Savoldo B., Hoyos V., Dutour A., Anichini A., Dotti G., Brenner M. K., Immunotherapy of metastatic melanoma using genetically engineered GD2-specific T cells Clinical Cancer Research 2009 15 18 5852 5860
84. Peng W., Ye Y., Rabinovich B. A., Liu C., Lou Y., Zhang M., Whittington M., Yang Y., Overwijk W. W., Lizée G., Hwu P., Transduction of tumor-specific T cells with CXCR2 chemokine receptor improves migration to tumor and antitumor immune responses Clinical Cancer Research 2010 16 22 5458 5468
85. Zito C., Kluger H. M., Immunotherapy for metastatic melanoma Journal of Cellular Biochemistry 2012 113 3 725 734
86. Hoos A., Eggermont A. M., Janetzki S., Hodi F., Ibrahim R., Anderson A., Humphrey R., Blumenstein B., Old L., Wolchok J., Improved endpoints for cancer immunotherapy trials Journal of the National Cancer Institute 2010 102 18 1388 1397
87. Kantoff P., Higano C., Shore N., Berger E. R., Small E. J., Penson D. F., Redfern C. H., Ferrari A. C., Dreicer R., Sims R. B., Xu Y., Frohlich M. W., Schellhammer P. F., Sipuleucel-T immunotherapy for castration-resistant prostate cancer The New England Journal of Medicine 2010 363 5 411 422
88. Topalian S. L., Drake C. G., Pardoll D. M., Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity Current Opinion in Immunology 2012 24 2 207 212
89. Toxicity and Activity of anti-PD-1 in Phase 1 Clinical Trials, Proceedings of the 102nd Annual Meeting of American Association for Cancer Research (AACR '11) April 2011 Orlando, Fla, USA